BEAT — HeartBeam, Inc.

HeartBeam (BEAT) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $4.7 million for Q1 2026, a 19% decrease in operating cash outflow compared to the same quarter last year.
• Cash Position: Ended Q1 with over $2 million; following an $11.5 million financing (including a $10 million public offering), pro forma cash balance is approximately $12.4 million.
• Cash Burn Projection: Expected cash outflow for 2026 revised to below $16 million, down from an initial estimate of $17 million to $19 million.

2. Strategic Updates and Business Highlights

• Commercial Partnerships: Signed partnerships with ClearCardio and Atelier Health, establishing a presence in key markets: New York City, Dallas, South Florida, and Southern California.
• Product Development: Completed the first working prototype of the 12-lead patch and initiated a pilot study for ischemia detection.
• Clinical Studies: Enrolled the first patient in the ALIGN-ACS pilot study, comparing HeartBeam's technology to standard ECGs in emergency settings, with enrollment ahead of schedule.
• AI Collaboration: Partnered with Mount Sinai to develop next-generation algorithms for heart attack detection and wellness assessments.

3. Forward Guidance and Outlook

• Revenue Expectations: Anticipate some revenue in Q2 2026, but focus remains on building partnerships and deepening adoption rather than immediate revenue generation.
• Long-Term Goals: Targeting 30,000 patients for breakeven, with a pathway to scale revenue in 2027 through expanded sales efforts and deeper adoption within existing accounts.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The company faces competition in the cardiac monitoring space, particularly from established players in the ambulatory monitoring market.
• Regulatory Risks: The success of the ALIGN-ACS pilot study and subsequent pivotal study is crucial for FDA approval and market entry, introducing inherent risks.
• Patient Adoption: While initial feedback from physicians is positive, actual patient adoption rates remain uncertain, which could affect revenue projections.

5. Notable Q&A Insights

• Patient Management: The number of patients managed by anchor partners was not disclosed, but the focus is on a target of 150,000 patients in the preventative concierge market.
• Pricing Strategy: Pricing is expected to be in the $750 to $1,000 range annually, with no pushback from early adopters.
• Clinical Study Details: The ALIGN-ACS study is expected to enroll 100-120 patients, with completion anticipated by the end of Q3 2026. The HEADSTART-ACS study in Indonesia will involve approximately 500 patients and is government-sponsored.
• Marketing Strategy: The company does not plan to pursue direct-to-consumer advertising but will leverage partnerships with concierge practices to drive patient adoption.
• Revenue Modeling: Revenue is expected to be straight-lined throughout the year, with most customers likely to pay upfront for the first year.

This summary encapsulates the key points from HeartBeam's Q1 2026 earnings call, highlighting both the progress made and the challenges ahead as the company seeks to establish its innovative cardiac monitoring solutions in the market.